Bacterial Sialadenitis Market Owing To Growing Prevalence of Sialadenitis
Market Overview:
Bacterial sialadenitis, also known as infective sialadenitis, is an infection and swelling of one or more of the salivary glands. The common symptoms include swelling of the salivary gland(s), pain or tenderness near the swollen gland, fever, and difficulty opening the mouth fully. The condition is usually caused by a bacterial infection, most commonly Staphylococcus aureus or Streptococcus pneumoniae. Treatment involves prescription of antibiotics such as penicillin to treat the infection.
The global Bacterial Sialadenitis Market Share is estimated to be valued at US$ 1.90 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growth in the global bacterial sialadenitis market is primarily driven by the rising prevalence of sialadenitis across the globe. According to the American College of Rheumatology, the prevalence rate of sialadenitis among adults in the U.S. is estimated to be 1.7 cases per 100,000 adults. Similarly, the Mayo Clinic reports an annual incidence rate of 27 cases per 100,000 individuals. The increasing incidence and prevalence is expected to drive the market growth over the forecast period. Additionally, development of novel antibiotics and drug formulations for treatment of bacterial sialadenitis is also expected to boost the market growth during the forecast period. However, availability of alternative treatment therapies may hinder the market growth.
SWOT Analysis
Strength:
1. Increased awareness about symptoms and available treatment options is expected to drive the market.
2. Strong research activities to develop new and more effective drugs and therapeutics.
3. Availability of innovative drugs with minimal side effects.
Weakness:
1. Limited understanding of the exact causes of bacterial sialadenitis poses challenges in diagnosis and treatment.
2. High costs associated with treatment and drug development.
Opportunity:
1. Untapped emerging markets offer lucrative opportunities for players.
2. Evolution of telemedicine and remote monitoring tools opens new avenues.
Threats:
1. Strong competition from generic drug manufacturers exerts pricing pressure on leading brands.
2. Stigma associated with chronic diseases hampers patients seeking timely medical help.
Key Takeaways
The global bacterial sialadenitis market is expected to witness high growth, exhibiting CAGR of 5.6% over the forecast period, due to increasing prevalence of chronic diseases such as Sjögren's syndrome.
Regional analysis
North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to developed healthcare infrastructure, high awareness about the disease, and new product launches. Asia Pacific bacterial sialadenitis market is slated to grow at fastest pace during the analysis period due to rising geriatric population, increasing healthcare spending, and growing research initiatives.
Key players
Key players operating in the bacterial sialadenitis market are Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc,Novartis AG,Sanofi S.A.,Johnson & Johnson,Abbott Laboratories,Eli Lilly and Company,AstraZeneca plc,Bayer AG,Bristol-Myers Squibb Company,Roche Holding AG,Teva Pharmaceutical Industries Ltd.,Mylan N.V.,Allergan plc.
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian